Clinical Efficacy of Ulinastatin Combined with Meglumine Adenosine Cyclophosphate in the Treatment of Acute Myocardial Infarction.
Journal
Computational and mathematical methods in medicine
ISSN: 1748-6718
Titre abrégé: Comput Math Methods Med
Pays: United States
ID NLM: 101277751
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
revised:
11
03
2022
accepted:
21
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
30
4
2022
Statut:
epublish
Résumé
Ulinastatin, a common adjuvant drug in the clinical treatment of acute circulatory failure, has a good effect on various inflammatory diseases. In this study, we aim to explore the clinical efficacy of ulinastatin combined with meglumine adenosine cyclophosphate in patients with acute myocardial infarction (AMI) and its effect on cardiac function and endothelial function of patients. 100 AMI patients treated in our hospital (February 2020-October 2020) were randomly chosen and divided into group J and group Q, with 50 cases in each group. Group Q was treated with meglumine adenosine cyclophosphate only, while group J was treated with ulinastatin combined with meglumine adenosine cyclophosphate to compare the treatment efficiency, cardiac structure indexes, cardiac systolic function, blood lipid levels, vascular endothelial function, QLI (quality of life) scores, BI indexes, and FMA (motor function) scores between the two groups. The treatment efficiency, QLI score, BI index, and FMA score in group J were notably higher compared with group Q (
Identifiants
pubmed: 35479188
doi: 10.1155/2022/2172412
pmc: PMC9038408
doi:
Substances chimiques
Glycoproteins
0
Meglumine
6HG8UB2MUY
Adenosine
K72T3FS567
urinastatin
OR3S9IF86U
Types de publication
Journal Article
Randomized Controlled Trial
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
2172412Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Zhenying Zhang et al.
Déclaration de conflit d'intérêts
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Medicine (Baltimore). 2021 Mar 19;100(11):e24984
pubmed: 33725969
Sci Rep. 2021 Mar 18;11(1):6307
pubmed: 33737645
Int J Cardiol Heart Vasc. 2021 Mar 11;33:100748
pubmed: 33748402
Int Immunopharmacol. 2020 Aug;85:106643
pubmed: 32473570
Ren Fail. 2020 Nov;42(1):137-145
pubmed: 31984833
Angiology. 2021 Apr;72(4):339-347
pubmed: 33233917
Saudi J Biol Sci. 2020 Aug;27(8):2076-2081
pubmed: 32742181
Medicine (Baltimore). 2020 Dec 4;99(49):e23361
pubmed: 33285716
Minerva Med. 2020 Dec 15;:
pubmed: 33319973
Clin Hemorheol Microcirc. 2020;75(2):135-142
pubmed: 31903986
Clin Rheumatol. 2021 Apr;40(4):1321-1329
pubmed: 32845439
J Physiol Biochem. 2020 Nov;76(4):573-586
pubmed: 32794154
Heart Vessels. 2021 Oct;36(10):1484-1495
pubmed: 33743047
Antioxidants (Basel). 2021 Mar 11;10(3):
pubmed: 33799852
Anim Nutr. 2018 Sep;4(3):260-264
pubmed: 30182065
Curr Drug Targets. 2021;22(2):192-201
pubmed: 32972339
Medicine (Baltimore). 2021 Mar 26;100(12):e25159
pubmed: 33761689
Am J Emerg Med. 2021 Jul;45:525-526
pubmed: 32703606